-
Mashup Score: 1Tisagenlecleucel Unsuccessful as Second-line Treatment in Aggressive B-cell non-Hodgkin Lymphoma - 3 year(s) ago
Tisagenlecleucel in aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint in the BELINDA study, in event-free survival compared to standard of care treatment. The pivotal phase 3, a randomized, open label, multicenter trial from 73 sites and 18 countries compared two treatment strategies in patients with aggressive B-cell non-Hodgkin lymphoma with primary refractory disease, or…
Source: video.mdalert.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2Investigational Agent Could Change Treatment of HER2-positive Metastatic Gastric Cancer - 4 year(s) ago
Researchers are hoping to find a new alternative to traditional chemotherapy to help treat HER2-positive metastatic gastric cancer, with later line treatments providing limited results which also take a toll on already fragile patients. Results of the phase II DESTINY-Gastric01 trial showed trastuzumab deruxtecan can improve overall response and survival rates, while also avoiding some of the…
Source: video.mdalert.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to see trastuzumab deruxtecan come to Gastric cancer, a rare drug with activity after other HER2-targeted therapies: https://t.co/BaACIpaczF @MDAlertSTAT
-
Tisagenlecleucel Unsuccessful as Second-line Treatment in Aggressive B-cell non-Hodgkin Lymphoma #lymsm #CARTcell https://t.co/q4IZ7aV2yE